Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
01/23/2023 | 125.39% | SVB Leerink | $23 → $19 | Maintains | Outperform |
11/18/2022 | 125.39% | JP Morgan | $20 → $19 | Maintains | Overweight |
08/24/2022 | 172.84% | Mizuho | $25 → $23 | Maintains | Buy |
07/26/2022 | 255.87% | SVB Leerink | $27 → $30 | Maintains | Outperform |
05/24/2022 | 125.39% | Goldman Sachs | $24 → $19 | Maintains | Buy |
05/06/2022 | 220.28% | SVB Leerink | $26 → $27 | Maintains | Outperform |
03/16/2022 | 160.97% | HC Wainwright & Co. | $24 → $22 | Maintains | Buy |
03/11/2022 | 113.52% | JP Morgan | $21 → $18 | Maintains | Overweight |
03/09/2022 | 208.42% | SVB Leerink | $25 → $26 | Maintains | Outperform |
03/04/2022 | 196.56% | SVB Leerink | $24 → $25 | Maintains | Outperform |
12/28/2021 | 184.7% | HC Wainwright & Co. | $88 → $24 | Maintains | Buy |
12/28/2021 | 184.7% | SVB Leerink | $66 → $24 | Maintains | Outperform |
11/19/2021 | 682.92% | SVB Leerink | $68 → $66 | Maintains | Outperform |
10/25/2021 | 943.89% | HC Wainwright & Co. | $87 → $88 | Maintains | Buy |
10/04/2021 | 706.64% | SVB Leerink | $66 → $68 | Maintains | Outperform |
09/10/2021 | 789.68% | B of A Securities | → $75 | Upgrades | Neutral → Buy |
08/06/2021 | 682.92% | SVB Leerink | $71 → $66 | Maintains | Outperform |
05/21/2021 | 848.99% | UBS | → $80 | Initiates Coverage On | → Buy |
05/07/2021 | 848.99% | Goldman Sachs | $92 → $80 | Maintains | Buy |
03/23/2021 | 789.68% | SVB Leerink | $67 → $75 | Maintains | Outperform |
03/04/2021 | 920.17% | Mizuho | $56 → $86 | Maintains | Buy |
02/09/2021 | 884.58% | Goldman Sachs | → $83 | Reinstates | → Buy |
01/11/2021 | 932.03% | HC Wainwright & Co. | $64 → $87 | Maintains | Buy |
12/10/2020 | 659.19% | HC Wainwright & Co. | $53 → $64 | Maintains | Buy |
12/04/2020 | 421.95% | SVB Leerink | $39 → $44 | Maintains | Outperform |
10/12/2020 | 528.71% | HC Wainwright & Co. | $50 → $53 | Maintains | Buy |
06/25/2020 | 350.77% | B of A Securities | → $38 | Initiates Coverage On | → Neutral |
05/19/2020 | 481.26% | BTIG | → $49 | Initiates Coverage On | → Buy |
05/14/2020 | 362.63% | SVB Leerink | $41 → $39 | Reiterates | → Outperform |
04/13/2020 | 493.12% | HC Wainwright & Co. | → $50 | Initiates Coverage On | → Buy |
03/03/2020 | 410.08% | JP Morgan | $38 → $43 | Maintains | Overweight |
02/19/2020 | 504.98% | Mizuho | → $51 | Initiates Coverage On | → Buy |
07/26/2019 | 327.05% | Raymond James | → $36 | Initiates Coverage On | → Outperform |
07/22/2019 | 350.77% | JP Morgan | → $38 | Initiates Coverage On | → Overweight |
07/22/2019 | 350.77% | Jefferies | → $38 | Initiates Coverage On | → Buy |
07/22/2019 | 303.32% | SVB Leerink | → $34 | Initiates Coverage On | → Outperform |
07/22/2019 | 398.22% | Goldman Sachs | → $42 | Initiates Coverage On | → Buy |
07/22/2019 | 493.12% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
07/22/2019 | 481.26% | BMO Capital | → $49 | Initiates Coverage On | → Outperform |
What is the target price for BridgeBio Pharma (BBIO)?
The latest price target for BridgeBio Pharma (NASDAQ: BBIO) was reported by SVB Leerink on January 23, 2023. The analyst firm set a price target for $19.00 expecting BBIO to rise to within 12 months (a possible 125.39% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BridgeBio Pharma (BBIO)?
The latest analyst rating for BridgeBio Pharma (NASDAQ: BBIO) was provided by SVB Leerink, and BridgeBio Pharma maintained their outperform rating.
When is the next analyst rating going to be posted or updated for BridgeBio Pharma (BBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BridgeBio Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BridgeBio Pharma was filed on January 23, 2023 so you should expect the next rating to be made available sometime around January 23, 2024.
Is the Analyst Rating BridgeBio Pharma (BBIO) correct?
While ratings are subjective and will change, the latest BridgeBio Pharma (BBIO) rating was a maintained with a price target of $23.00 to $19.00. The current price BridgeBio Pharma (BBIO) is trading at is $8.43, which is out of the analyst's predicted range.